secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001437749-24-005986
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene reports positive long-term results from VISIONARY-MS LTE trial for CNM-Au8 in MS
--------------------------------------------------------------------------------

- Long-term CNM-Au8 treatment showed significant improvement in vision (LCLA) through 35 months, p<0.0001, mean +8.70 letters.
- Cognition improved via SDMT through 35 months, p<0.0001, mean +8.03 points.
- Global neurological function (mMSFC) improved through 35 months, p=0.018.
- No serious adverse events attributed to CNM-Au8; treatment well-tolerated with 94% compliance.
- Data presented at ACTRIMS Forum 2024; 55 of 69 eligible participants continued in LTE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774924005986/0001437749-24-005986-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774924005986/clnn20240228_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-005986

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer